Current treatments for osteoporosis include antiresorptive therapies (bisphosphonates, estrogens, selective estrogen receptor modulators, calcitonin, and monoclonal antibodies such as denosumab) and anabolic therapies (teriparatide, abaloparatide, and the anti-sclerostin monoclonal antibody romosozumab, which indirectly activates Wnt signaling by blocking a negative regulator, sclerostin). Here, ESR1 is linked to osteoporosis.